| International
Cancer Vaccine Symposium
In Washington DC 2006
“Current Clinical and Laboratory Advances in Cancer Vaccines and Immunotherapies”
February 5-7, 2006 North Bethesda Marriott Hotel, Bethesda, Maryland, USA
SUNDAY 5 FEBRUARY 2006
18:30 Speakers' Reception/Dinner at North Bethesda
Marriott Hotel
MONDAY 6 FEBRUARY 2006
7:30 Registration
OPENING:
8:30 Welcome Address
Dr. Lowell T. Harmison, Chairman, World Immuno-Society for Health, Switzerland
Dr. Kenichiro Hasumi, Chairman, Hasumi International Research Foundation, USA
KEYNOTE SPEAKER:
8:40 On Immunity Against Viruses and Tumours
Professor Rolf Zinkernagel, University
Hospital, Zurich, Switzerland
SESSION 1: chaired
by Dr. Jeffrey Schlom, National Cancer Institute, NIH,
USA
10:00 A Novel DNA-based Vaccines for Cancer Therapy
Dr. Ralph A. Reisfeld, The Scripps
Research Institute, USA
10:30 Design and Development of Recombinant
Vaccines for the Therapy of Carcinomas
Dr. Jeffrey Schlom, National Cancer
Institute, NIH, USA
11:00 Immunotherapy of Established Papilloma
Virus-Induced (pre-)Malignant Lesions in Mice, Rabbits
and Patients
Professor Cornelis Melief, University
Hospital Leiden, the Netherlands
11:30 Design and Optimization of Peptide-Based
Vaccines for Cancer
Dr. Esteban Celis, Louisiana State
University Health Science Center, USA
SPECIAL REMARKS:
13:00 Current Research and Drug Discovery in a
New Era
Dr. John E. Niederhuber, Deputy
Director, National Cancer Institute, NIH, USA
SESSION 2: chaired by Dr. Tyler Curiel, Tulane Medical School, USA
13:30 Tumour Cell-Dendritic Cell Fusion Vaccine
Dr. David Avigan, Beth Israel
Deaconess Medical Center, USA
14:00 Overcoming Negative Regulation to Enhance
Cancer Vaccines and Immunosurveillance
Dr. Jay Berzofsky, National Cancer
Institute, NIH, USA
14:30 Regulatory T Cell Depletion in Cancer:
Immunologic and Clinical Correlates
Dr. Tyler Curiel, Tulane Medical
School, USA
15:00 Autoimmunity and Vaccination in Melanoma
Dr. Jeffrey S. Weber, USC/Norris
Comprehensive Cancer Institute, USA
SESSION 3: chaired by Dr. Dean Mann, University of Maryland Baltimore, USA
15:50 Prevention of HPV Infection and Cervical
Cancer
Dr .Douglas Lowy, National Cancer Institute, NIH, USA
16:20 Innate Immunity in Cancer and Hematopoietic
Cell Transplantation
Dr. Jeffrey S. Miller, University of Minnesota, USA
16:50 Antigens Targeted in the Successful Immunosurveillance
of Tumor Progression are Candidates for Prophylactic Cancer
Vaccines
Dr. Olivera “Olja” J. Finn, University
of Pittsburgh, USA
TUESDAY 7 FEBRUARY 2006
SESSION 4: chaired by Dr. Ralph A. Reisfeld, The Scripps Research Institute, USA
8:30 Optimisation of Cancer Vaccines for Therapy
of The Common Solid Tumours
Professor Angus Dalgliesh, St.
George’s University of London, United Kingdom
9:00 Vaccines for Prostate Cancer ? a Translational
Journey from Conception to Phase III Clinical Studies
Dr. James L. Gulley, National
Cancer Institute, NIH, USA
9:30 Heat-Shock Proteins: Immunobiology and
Use in Cancer Vaccines
Professor Giorgio Parmiani,
Istituto Nazionale Tumori, Milano, Italy
SESSION 5: chaired by Dr. Ronald Levy, Stanford University School of Medicine, USA
10:20 Therapeutic Vaccination for Lymphoid Malignancy
Dr. Ronald Levy, Stanford University
School of Medicine, USA
10:50 Dendritic Cell Vaccination and Amplification
Strategies
Professor Gerold Schuler, University Hospital of Erlangen,
Germany
11:20 Imiquimod-Induced Regression of Cutaneous
Neoplasms: Cellular and Molecular Mechanisms
Professor Georg Stingl, University of Vienna Medical School,
Austria
11:50 Dendritic Cell as Therapeutic Vaccines
in Cancer
Dr. Karoline Palucka, Baylor Institute for Immunology
Research, USA
SESSION 6: chaired by Dr. Elizabeth M. Jaffe, Johns Hopkins, USA
13:20 Tipping the Immune System Balance in Favor
of Effective Anti-Cancer Interventions
Dr. Elizabeth M. Jaffe, Johns Hopkins, USA
13:50 Recent Progress in Human Cancer Immunotherapy
Dr. Steven A. Rosenberg, National Cancer Institute, NIH,
USA
14:20 Checkpoint Blockade in Cancer Immunotherapy
Dr. James P. Allison, Howard Hughes Medical Institute/Memorial
Sloan-Kettering Cancer Center, USA
SESSION 7: chaired by Dr. Crystal L. Mackall, National Cancer Institute, NIH, USA
15:10 The Present Status of Active Specific Immunotherapy
with Canvaxin Whole-Cell Vaccine after Resection of Metastatic
Melanoma
Dr. Donald L. Morton, John Wayne Cancer Institute, USA
15:40 Evaluation of Antigens for Vaccination
Against Prostate Cancer
Professor Peter Rieber, Technical University Dresden,
Germany
16:10 Contrasting IL-2 and IL-7 in Cancer Immunotherapy
and Immune Reconstitution
Dr. Crystal L. Mackall, National Cancer Institute, NIH,
USA
FUTURE VIEWS:
16:40 Professor Hans Wigzell, Karolinska Institutet,
Sweden
CLOSING:
|
